REMEGEN (09995) Stock Price, News, Quotes-Moomoo

HK Stock MarketDetailed Quotes

09995 REMEGEN

Watchlist

16.040
-0.780-4.64%

Trading Dec 13 15:53 CST

8.73BMarket Cap-5.07P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | RemeGen Co Ltd: Safety Profile in Phase III Study of Disitamab Vedotin Was Consistent With Past Disitamab Vedotin Use Experience
Reuters18:25 ET
Express News | RemeGen Co Ltd: Disitamab Vedotin Significantly Improved Progression-Free Survival Versus Lapatinib Plus Capecitabine
Reuters18:24 ET
2024 SABCS|Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer With Liver Metastasis
PR Newswire18:20 ET
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
Gelonghui FinanceDec 8 23:10 ET
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
cls.cnDec 8 03:48 ET
Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen
Yahoo FinanceDec 2 04:31 ET

Comments

Moomoo AI

Mar 22 20:21

RemeGen's high P/S ratio, driven by current investor sentiment and future expectations, may be concerning given the company's less than stellar revenue forecasts. Unless conditions improve, these prices may not be reasonable.

RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 29% But Its Business Is Yet to Catch Up

Moomoo AI

Feb 6 19:09

Despite RemeGen's subdued revenue growth projections, it trades at a P/S ratio similar to the industry, suggesting investors may be less bearish than analysts. However, its weaker revenue outlook could risk a share price decline and pose a risk to shareholders.

Some Confidence Is Lacking In RemeGen Co., Ltd. (HKG:9995) As Shares Slide 47%

ကင်ချီ

Jan 24 21:46

$REMEGEN (09995.HK)$ This shitty stock

Spinee

Jan 17 02:21

HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off

$Hang Seng Index (800000.HK)$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN (09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B (02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH (01873.HK)$ ...

SEA Hedge

Dec 15, 2021 01:56

In FT's story, The commerce department is expected to place more than two dozen Chinese companies on the entity list on Thursday, including some involved in biotechnology.
The news triggers the sell-off in Hong Kong.
$WUXI BIO (02269.HK)$ $WUXI APPTEC (02359.HK)$ $CLOVER BIO-B (02197.HK)$ $REMEGEN (09995.HK)$